Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.64 |
| ▸ | TCF7 | P36402 | 2/20 | 0.64 |
| ▸ | CLPP | Q16740 | 2/20 | 0.64 |
| ▸ | BCL9 | O00512 | 1/20 | 0.64 |
| ▸ | TCF4 | P15884 | 1/20 | 0.64 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13773477 | 0.96 | CLPP (0.62) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL14505456 | 0.95 | CTNNB1 (0.58) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL14047461 | 0.95 | CTNNB1 (0.58) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL14309338 | 0.94 | CLPP (0.57) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL13773475 | 0.94 | CLPP (0.57) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL14319405 | 0.94 | CLPP (0.57) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL13773533 | 0.94 | CLPP (0.56) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL13773521 | 0.93 | CLPP (0.56) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL13773486 | 0.93 | CTNNB1 (0.62) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL14504257 | 0.92 | CLPP (0.56) | CTNNB1TCF7CLPPBCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-8293743-B2 | Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells | CHOONGWAE PHARMA CORPORATION (KR) | 2012-10-23 | — | — | US | disclosed |
| US-8293743-B2 | Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells | CHOONGWAE PHARMA CORPORATION (KR) | 2012-10-23 | — | — | US | disclosed |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
| WO-2007056513-A1 | α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | INSTITUTE FOR CHEMICAL GENOMICS (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056593-A2 | α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORPORATION (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | CTNNB1 513/4885TCF7 1040/4885CLPP 2188/4885 |
| US-20080242669-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | NR3C1, RXFP3, NR2E3 | CTNNB1 1791/4885TCF7 1456/4885CLPP 4872/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | CTNNB1 101/4885TCF7 76/4885CLPP 2482/4885 |
| US-20090176742-A1 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS | RXFP3, NR3C1, NR2E3 | CTNNB1 1661/4885TCF7 1366/4885CLPP 4874/4885 |
| US-20100069333-A1 | ALPHA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | MCL1, HNF4A, THPO | CTNNB1 101/4885TCF7 91/4885CLPP 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.